Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Apr 13;141(15):1787-1789.
doi: 10.1182/blood.2023019642.

FXII and sickle cell: the clot thickens

Arun S Shet  1
Affiliations
Editorial

FXII and sickle cell: the clot thickens

Arun S Shet. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The author declares no competing financial interests.

Figures

None
Both humans with SCD and Townes sickle mice demonstrate evidence for FXIIa and contact-pathway factor activation at baseline and display elevated surface FXIIa on neutrophils. TNFα challenge in sickle mice is associated with FXII-dependent activation of the complement pathway of inflammation and the intrinsic pathway of coagulation. Recapitulation of the sickle phenotype by transplantation of HbSS bone marrow into FXII-deficient mice (HbSS/FXII–/–) attenuated these effects. Similarly, genetic FXII deficiency (HbSS/FXII–/–) and treatment with an antibody to FXII (15D10) attenuated vascular stasis, and hepatic and renal congestion in sickle mice challenged with heme to induce vascular stasis, a model mimicking acute VOC in humans with SCD. Infusion of the antibody 15D10 also attenuated electrolytically induced femoral venous thrombosis and reduced stroke infarct volume and neutrophil adhesion in the pial blood vessels of sickle mice. Illustration by Bindu Gopalan.
See this image and copyright information in PMC

Comment on

  • Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease.
    Sparkenbaugh EM, Henderson MW, Miller-Awe M, Abrams C, Ilich A, Trebak F, Ramadas N, Vital S, Bohinc D, Bane KL, Chen C, Patel M, Wallisch M, Renné T, Gruber A, Cooley B, Gailani D, Kasztan M, Vercellotti GM, Belcher JD, Gavins FE, Stavrou EX, Key NS, Pawlinski R. Sparkenbaugh EM, et al. Blood. 2023 Apr 13;141(15):1871-1883. doi: 10.1182/blood.2022017074. Blood. 2023. PMID: 36706361 Free PMC article.

References

    1. Sparkenbaugh EM, Henderson MW, Miller-Awe M, et al. Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease. Blood. 2023;141(15):1871–1883. - PMC - PubMed
    1. Chantrathammachart P, Mackman N, Sparkenbaugh E, et al. Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood. 2012;120(3):636–646. - PMC - PubMed
    1. Sparkenbaugh E, Pawlinski R. Prothrombotic aspects of sickle cell disease. J Thromb Haemost. 2017;15(7):1307–1316. - PubMed
    1. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202(2):271–281. - PMC - PubMed
    1. Conran N, De Paula EV. Thromboinflammatory mechanisms in sickle cell disease—challenging the hemostatic balance. Haematologica. 2020;105(10):2380–2390. - PMC - PubMed